Projet MAST4HEALTH (Horizon 2020, appel à projets 2015)
Action : Staff Exchanges
Panel : Life Sciences
Statut du projet : CLOSED

MAST4HEALTH is set on the concept of a multidisciplinary approach to assess a non-pharmacological intervention for managing NAFLD/NASH, one of the most common complications of obesity and diabetes mellitus in Western populations affecting approximately 50% of diabetics and 76% of obese patients. Because of limitations in current NAFLD treatment therapies, many new efforts focus on exploring non-pharmacologic means for managing the disease and in particular through dietary substances or bioactive phytochemicals in fruits, vegetables, and plants or their products. MAST4HEALTH aims at exploring the effect of Mastiha, a natural product of Greece which was recently shown to possess antioxidant/anti-inflammatory and lipid lowering properties. We designed a multicenter randomized double blind placebo controlled (parallel arm) clinical trial to test the effectiveness of Mastiha supplement as new non-pharmacologic strategy for NAFLD/NASH treatment. MAST4HEALTH will explore gene-diet interactions, more specifically the potential personalized activity of the Mastiha, and correlate genetic and epigenetic markers with metabolomic and intestinal microbiota profiles pre- and post-intervention. The effectiveness of the proposed intervention will be evaluated via clinical and laboratory markers of the disease. To this end, MAST4HEALTH will train a number of researchers and PhD students in multidisciplinary approaches of this survey. MAST4HEALTH is expected to build and enhance cooperation among partners meanwhile strengthening the interaction between our academic and non-academic sectors

Mots clés : nafld, mastiha, obesity, genomics, gene nutrient interaction

Participants :
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 135000.0 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 162000.0 €
- Sanofi (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 81000.0 €
- Harokopio University of Athens (Grèce) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 441000.0 €
- Randox (United Kingdom) (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 153000.0 €
- National Research Council (Italie) — Partner, beneficiary, Recherche, subvention : 121500.0 €
- University of East Sarajevo (Bosnie-Herzégovine) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 13500.0 €
- Perspectum ltd (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 157500.0 €
- University of Milan (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 63000.0 €
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Espagne) — Partner, beneficiary, Recherche, subvention : 117000.0 €
- Marascio fernando (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 108000.0 €
- Enosis mastichoparagogon chiou (Grèce) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 297000.0 €
- Istituti di Ricovero e Cura a Carattere Scientifico (Italie) — Partner, beneficiary, Autres, subvention : 9000.0 €
- Biotech vana sl (Espagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 157500.0 €
- University of Novi Sad (Serbie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 108000.0 €